FINWIRES · TerminalLIVE
FINWIRES

SHA:600436

3 stories mentioning SHA:600436Updated just now

Every FINWIRES story that references SHA:600436, newest first.

Asia

Zhangzhou Pientzehuang Pharmaceutical Enrolls First Patient in Phase Three Drug Trial

Zhangzhou Pientzehuang Pharmaceutical (SHA:600436) said it enrolled the first participant in the third phase trial of Changji'an capsules for diarrhea-predominant irritable bowel syndrome with liver-qi invading spleen pattern.The multi-center, double-blind, placebo-controlled study targets an eight-week stool consistency response rate as its primary endpoint, according to a Wednesday filing with the Shanghai bourse.Shares of the drug company closed 3% lower Wednesday.

SHA:600436
Asia

Zhangzhou Pientzehuang Pharmaceutical's Attributable Profit Slides 26% in Q1

Zhangzhou Pientzehuang Pharmaceutical's (SHA:600436) attributable profit fell 26% to 743.5 million yuan in the first quarter from 999.8 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.Earnings per share at the drug company decreased to 1.23 yuan from 1.66 yuan in the prior-year period.Operating revenue declined 13% year over year to 2.74 billion yuan from 3.14 billion yuan.

SHA:600436
Asia

Zhangzhou Pientzehuang Pharmaceutical's Attributable Profit Slides 27% in 2025

Zhangzhou Pientzehuang Pharmaceutical's (SHA:600436) attributable profit fell 27% to 2.16 billion yuan in 2025 from 2.98 billion yuan in 2024, according to a Thursday filing with the Shanghai bourse.Earnings per share at the drug company decreased to 3.58 yuan from 4.93 yuan in the previous year.Operating revenue declined 17% year over year to 9 billion yuan from 10.8 billion yuan.

SHA:600436

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600436 in your portfolio
WheelAI
WheelAI
Analyze SHA:600436 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600436